Roche’s Alecensa wins wider US approval for lung cancer

7th November 2017 Uncategorised 0

Roche group Genentech says its application to expand the use of Alecensa to include first-line treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) has been approved by US regulators.

More: Roche’s Alecensa wins wider US approval for lung cancer
Source: News